19 Aug 2023 BITT Announces FDA Acceptance of IND for TNFR2 Antibody
19 Aug 2023 EYLEA HD (aflibercept) Injection 8 mg Approved by FDA for Treatment of Wet Age-related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)
19 Aug 2023 Veopoz™ (pozelimab-bbfg) Receives FDA Approval as the First Treatment for Children and Adults with CHAPLE Disease
19 Aug 2023 Fibroblast Activation Protein (FA): an ideal tumor stroma target for payload delivery
18 Aug 2023 Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific
18 Aug 2023 Akeso Announced First Patient Dosed in Phase 3 Trial of Ivonescimab versus Tislelizumab for First-line Treatment of Squamous NSCLC
18 Aug 2023 Inmagene's anti-OX40 mAb demonstrated an extended half-life and a favorable safety profile in a Phase I study
18 Aug 2023 Odronextamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
18 Aug 2023 European Commission Approves Reduced Dosing Frequency for Janssen’s Bispecific Antibody TECVAYLI (teclistamab)
18 Aug 2023 NextPoint Therapeutics Announces First Patient Dosed in Phase 1a/b Clinical Trial of NPX267, a Novel Therapeutic Targeting KIR3DL3 to Reactivate Exhausted T and NK Cells in HHLA2+ Solid Tumors
17 Aug 2023 Folate Receptor alpha: a validated target for application of novel drug modalities
17 Aug 2023 Tonix Pharmaceuticals Initiates Phase 1 Trial of TNX-1500 (Fc-modified humanized anti-CD40L mAb) in Healthy Volunteers
17 Aug 2023 Elevation Oncology Announces First Patient Dosed in the Phase 1 Clinical Trial Evaluating EO-3021
17 Aug 2023 Innovent Announces the NMPA Approval of SINTBILO® (Tafolecimab Injection) for the Treatment of Adult Patients with Primary Hypercholesterolemia and Mixed Dyslipidemia
16 Aug 2023 Tiziana Life Sciences Announces FDA IND Clearance of Intranasal Foralumab for the Treatment of Alzheimer’s Disease
16 Aug 2023 Novel biologic Ab-IPL-IL-17™ shows promise for rheumatoid arthritis and inflammatory bowel disease
16 Aug 2023 OnCusp Therapeutics Receives FDA Clearance for the Phase 1 Clinical Trial of CUSP06, Targeting Ovarian Cancer and Other Advanced Solid Tumors
16 Aug 2023 Inmagene's OX40 mAb, with an extended half-life and silenced ADCC, enters POC study in Atopic Dermatitis
15 Aug 2023 IGF-1R- and IGF-1 Targeted Immunotherapy Pipeline Review
15 Aug 2023 Pfizer’s ELREXFIO™ Receives U.S. FDA Accelerated Approval for Relapsed or Refractory Multiple Myeloma
15 Aug 2023 Sandoz announces positive results from Mylight Phase lll study for biosimilar aflibercept
12 Aug 2023 Zumutor Biologics Inc announces FDA clearance of IND application of ZM008, a novel monoclonal antibody drug against multiple solid cancers
12 Aug 2023 Bio-Thera Solutions Announces Positive Phase 1 Clinical Data for BAT8006 (Folate-Receptor-α-ADC) and Presents Phase 1 Dose Escalation Study at the Bethune Obstetrics and Gynecology Forum
11 Aug 2023 Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
11 Aug 2023 Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up